Incannex Healthcare Inc. (IXHL)
Market Closed
15 Dec, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 38
-0.04
-9.13%
After Hours
$
+0.01 +3.36% 0. 40
124.17M Market Cap
- P/E Ratio
0% Div Yield
12,346,444 Volume
0 Eps
$ 0.42
Previous Close Day Range
0.38 0.43
Year Range
0.08 2.25
Want to track IXHL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days
Summary
IXHL closed today lower at $0.38, a decrease of 9.13% from yesterday's close, completing a monthly increase of 6.78% or $0.02. Over the past 12 months, IXHL stock lost -81.87%.
IXHL is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2025, exceeded the consensus estimates by 0.39%. On average, the company has surpassed earnings expectations by 0.23%, based on the last three reports. The next scheduled earnings report is due on Feb 13, 2026.
Incannex Healthcare Inc. has completed 1 stock splits, with the recent split occurring on Nov 30, 2023.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 2 weeks ago
Incannex Healthcare Inc. (IXHL) FAQ
What is the stock price today?
The current price is $0.38.
On which exchange is it traded?
Incannex Healthcare Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is IXHL.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 124.17M.
When is the next earnings date?
The next earnings report will release on Feb 13, 2026.
Has Incannex Healthcare Inc. ever had a stock split?
Incannex Healthcare Inc. had 1 splits and the recent split was on Nov 30, 2023.
Incannex Healthcare Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Joel Bradley Latham CEO | NASDAQ (CM) Exchange | 45333L106 CUSIP |
| AU Country | 9 Employees | - Last Dividend | 30 Nov 2023 Last Split | 2 Mar 2022 IPO Date |
Overview
Incannex Healthcare Inc. is a clinical stage pharmaceutical development company focused on the cutting-edge research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. Catering to a wide range of medical conditions, the company is pioneering treatments for obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (including conditions such as ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other significant indications. With a commitment to leveraging the potential of cannabinoids and psychedelics for medical treatments, Incannex Healthcare is at the forefront of addressing unmet medical needs through innovative therapeutic solutions.
Products and Services
- APIRx-1801, APIRx-1802, and APIRx-1803: These products represent ultrapure forms of tetrahydrocannabinol (THC), CBD, and cannabigerol (CBG) respectively, developed for therapeutic applications.
- IHL-42X: A medicinal product that has completed Phase IIb clinical trial specifically for the treatment of obstructive sleep apnea (OSA).
- Psi-GAD: Undergoing Phase IIa clinical trial, this product demonstrates Incannex's venture into psychedelic-based therapy for generalized anxiety disorder.
- MedChew Dronabinol: A product that has shown efficacy in Phase Ia clinical trials for managing nausea and vomiting associated with chemotherapy.
- CanChew Plus: This product has completed Phase IIa clinical trial for the treatment of irritable bowel syndrome, showcasing the potential of cannabinoids in gastrointestinal conditions.
- APIRx-1601, APIRx-1602, and APIRx-1603: Developed for the treatment of skin conditions such as vitiligo, psoriasis, and atopic dermatitis, these products have completed Phase IIa clinical trials.
- IHL-675A: This compound is explored for multiple indications including inflammatory lung disease, rheumatoid arthritis, and inflammatory bowel disease, having completed pre-clinical trials.
- IHL-216A: Aimed at treating traumatic brain injury and concussion, this product has also completed pre-clinical trials.
- Various Pre-Clinical Stage Products: Incannex is developing a wide range of products targeting pain and spasticity in multiple sclerosis (MedChew 1401), post-herpetic neuralgia (MedChew GB), Parkinson's disease (MedChew-1502), dementia (MedChew-1503), restless legs syndrome (MedChew RL), Crohn's disease (APIRx 1505 Flotex), inflammatory bowel disease (CanChew RX and SuppoCan), addiction treatments such as CheWell (cannabis addiction) and CanQuit variants (tobacco and opioid addiction), and others like APIRx-1701 for glaucoma and APIRx-1702 for dry eye syndrome, all of which are in pre-clinical trials stages.
Contact Information
Address: 207/11 Solent Circuit
Phone: 61 4 2570 3805
Website: https://www.incannex.com.au
2025 © Marketlog. All Rights Reserved.
